Abstract
Patients with melanoma in situ are at an increased risk of subsequent melanoma compared with the general population, but the risk of subsequent melanoma after initial melanoma in situ versus after initial invasive melanoma is not known. We sought to compare the risk of subsequent melanoma in the cohort whose first cancer was melanoma in situ to the risk in the cohort whose first cancer was invasive melanoma. In this cohort study, we identified individuals whose first cancer was either melanoma in situ or invasive melanoma from the Surveillance, Epidemiology, and End Results (SEER) program between 1973 and 2011 and used Cox proportional hazards models for comparison. Compared with the invasive melanoma cohort, the melanoma in situ cohort was more likely to develop subsequent melanoma of any stage after 2 years, subsequent invasive melanoma after 10 years, and subsequent melanoma in situ at all the time points (P < .001, P = .003, P < .001, respectively). Underreporting of melanomas, particularly melanoma in situ cases, and missing cases of subsequent melanomas as a result of patient migration from the SEER registry areas could affect results. Given the increased long-term risk of subsequent melanoma in the melanoma in situ cohor...Continue Reading
References
Dec 1, 1992·Journal of the American Academy of Dermatology·H K KohR A Lew
Oct 11, 1992·Cancer·S KangA J Sober
Jan 1, 1993·Clinical Oncology : a Journal of the Royal College of Radiologists·C A BaughanP J Perkins
Sep 17, 1998·Journal of the American Academy of Dermatology·T M JohnsonL Lowe
Sep 25, 1999·International Journal of Cancer. Journal International Du Cancer·C WassbergU Ringborg
Mar 16, 2000·Cancer·C M BalchK M McMasters
Apr 13, 2001·Cancer·L A DiFronzoD L Morton
Jul 10, 2002·Acta Oncologica·Eva Månsson-BrahmeUlrik Ringborg
Jan 28, 2003·Cancer·William B Goggins, Hensin Tsao
Jan 18, 2006·Cancer Causes & Control : CCC·Michael CooryIan Ring
Oct 16, 2009·The Journal of Investigative Dermatology·Vincent D Criscione, Martin A Weinstock
Mar 17, 2010·Archives of Dermatology·Porcia T BradfordMargaret A Tucker
Jul 9, 2010·The British Journal of Dermatology·J R MarsdenUNKNOWN British Association of Dermatologists Clinical Standards Unit
Oct 15, 2010·The Journal of Investigative Dermatology·Victor SiskindDavid C Whiteman
Aug 27, 2011·Journal of the American Academy of Dermatology·Christopher K BichakjianUNKNOWN American Academy of Dermatology
Nov 2, 2011·Journal of the American Academy of Dermatology·Ahmedin JemalPhyllis A Wingo
Nov 2, 2011·Journal of the American Academy of Dermatology·Appathurai BalamuruganSherri L Stewart
Dec 20, 2011·Swiss Medical Weekly·R DummerUNKNOWN Project Group Melanoma of the Swiss Group for Clinical Cancer Research
Dec 27, 2011·Journal of the American Academy of Dermatology·Joy H KunishigeJohn A Zitelli
Jul 5, 2012·The British Journal of Dermatology·R J T van der LeestE de Vries
Oct 16, 2012·Journal of the American Academy of Dermatology·Douglas GrossmanGlen M Bowen
Jun 1, 2013·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Annette PflugfelderUNKNOWN German Society of Dermatology
Aug 6, 2014·JAMA Dermatology·Danny R YouldenPeter D Baade
Citations
Sep 21, 2016·Journal of the American Academy of Dermatology·Claire S LeitchUNKNOWN Edinburgh Dermatology Virtual Journal Club
Sep 21, 2016·Journal of the American Academy of Dermatology·Hyemin Pomerantz, Martin A Weinstock
Nov 20, 2016·PloS One·Jia YuHui Lin
Jan 7, 2018·Applied Health Economics and Health Policy·Caroline G WattsAnne E Cust
Aug 12, 2017·International Journal of Cancer. Journal International Du Cancer·Deborah UtjésHanna Eriksson
Dec 4, 2019·The British Journal of Dermatology·E K McMenimanR A Sturm
Jun 6, 2019·Oncotarget·Florentia DimitriouPhil F Cheng
Jul 28, 2018·The Australasian Journal of Dermatology·J Mark ElwoodMarius Rademaker
Jun 5, 2019·Trials·P MurchieA McDonald
Jan 10, 2020·PeerJ·Jie XiongBihai Zhao
Nov 11, 2020·Cancer·Lilit KarapetyanJohn M Kirkwood